Τόμος 30 (2016) – Τεύχος 3 – Άρθρο 2 – Review of Clinical Pharmacology and Pharmacokinetics- Διεθνής Έκδοση – Volume 30 (2016) – Issue 3 – Article 2 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

By | | Irene Kotsalou, Άρθρο επισκόπησης - Review Article, Πλήρες Κείμενο στα Αγγλικά - Full Text in English, Φωτούλα Μπαμπάτσικου - Fotoula Babatsikou, Χαρίλαος Κουτής - Charilaos Koutis
Title Alzheimer’s Disease (AD): Global Public Health Concern with Individual and Socio-financial Impact
Author Fotoula Babatsikou1, Irene Kotsalou2, Charilaos Koutis3
Affilations 1Associate Professor of Nursing, Laboratory of Hygiene & Epidemiology, Technological Educational Institute (TEI) of Athens, Athens, Greece

2Scientific collaborator of Department of Public Health & Community Health, Laboratory of Hygiene & Epidemiology, Technological  Educational Institute (TEI) of Athens, Athens, Greece

3Professor of Hygiene, Epidemiology & Public Health, Department of Public Health & Community Health, Director of the Laboratory of Hygiene & Epidemiology, Technological  Educational Institute (TEI) of Athens, Athens, Greece
Citation Babatsikou F., Kotsalou I.,  Koutis C., : Alzheimer’s Disease (AD): Global Public Health Concern with Individual and Socio-financial Impact, Review Clin. Pharmakol. Pharmakokinet. Int. Ed. 30(1): 71-78 (2016)
Publication Date Accepted for publication (Final Version): November 28, 2016
Full Text Language English
Keywords Alzheimer’s disease, epidemiology, pathophysiology, treatment, socio-economic impact, future trends
Other Terms review article
Summary Alzheimer’s disease (AD) is by far the most common type of dementia in aging adults, and a substantial burden to patients and their families, their caregivers, and the healthcare system. Worldwide it is an increasingly significant public health issue, due to the dramatic increase of individuals affected both in high and low income countries and to the fact that the disease is a progressive degenerative one and still incurable. Epidemiologists estimate that patients with AD will reach 131.5 million by 2050, making the research for new treatments which stop the progression of disease increasingly urgent. Our review summarizes the current literature on epidemiology, etiology, pathophysiology, both clinical and radiological diagnosis of AD and presents the existing approved treatment and future trends of treatment under research on AD. Finally, we focus on the decisions made in 2015 during the G7 Global Action Against Dementia, reflecting the worldwide interest on this Global Public health problem which is often associated with a social stigma for the patients and their families and has a tremendous individual, social and financial impact.
References
  1. Ramirez-Bermudez J.: Alzheimer’s disease: critical notes on the history of a medical concept. Arch. Med. Res. 43(8): 595-599 (2012)
  2. Alzheimer’s association. Alzheimer’s Disease Facts and Figures- Executive Summary. Chicago, IL, 2009
  3. Kumar A., Singh A., Ekavali A.: A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol. Rep. 67(2): 195-203 (2015)
  4. Anand R., Gill K., Mahdi A.: Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76: 27-50 (2014)
  5. Bird T., Miller B.: Dementia. In: Fauci A.S., Baunwauld E., Kasper D.L., Hauser S.L., Longo D.L., Jameson J.L., Loscalzo J., editors. Harrison’s Principles of Internal Medicine. 17th ed, Columbus, OH: McGraw-Hill, 2536-2549 (2007)
  6. World Alzheimer Report 2015.: The Global impact of Dementia. An analysis of prevalence, impact, costs and trends. Published by Alzheimer’s Disease International (ADI), London (2015)
  7. Brunkan A., Goate A.: Presenilin function and gamma secretase activity. J. Neurochem. 93: 769-792 (2005)
  8. Goedert M., Spillantini M.: A century of Alzheimer’s disease. Science 314: 777-781 (2006)
  9. DeFina P., Moser R., Glenn M., Lichtenstein J., Fellus J.: Alzheimer’s Disease Clinical and Research Update for Health Care Practitioners. J. Aging Res. 2013, 1-9 (2013)
  10. Salawu F., Umar J., Olokoba A.: Alzheimer’s disease: A review of recent developments. Ann. Afr. Med. 10(2): 73-79 (2011)
  11. Jellinger K.: Head injury and dementia. Curr. Opin. Neurol. 17: 719-723 (2004)
  12. Rapp S., Espeland M., Shumaker S., Hendersen V., Brunner R., Manson J., Gass M.L.,Stefanick M.L., Lane D.S., Hays J., Johnson K.C., Coker L.H., Dailey M., Bowen D.; WHIMS Investigators: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA 289(54):  2663-2672 (2003)
  13. Shumaker S., Legault C., Rapp S., Thal L., Wallace R., Ockene J., Hendrix S.L.,Jones B.N. 3rd,Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J.; WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA 289(20): 2651-2662 (2003)
  14. Sidera C., Parsons R., Austen B.: The regulation of â-secretase by cholesterol and statins in Alzheimer’s disease. J. Neurol. Sci. 229: 269-273 (2005)
  15. Moreira P., Sautos M., Seica R., Oliveira C.: Brain mitochondrial dysfunction as a link between Alzheimer’s disease and diabetes. J. Neurol. Sci. 257: 206-214 (2007)
  16. Norton S., Matthews F., Barnes D., Yaffe K., Brayne C.: Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 13(8): 788-794 (2014)
  17. Francis P., Palmer A., Snape M., Wilcock G.: The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 66(2): 137-147 (1999).
  18. Korolev I.: Alzheimer’s Disease: A Clinical and Basic Science Review. MSRJ 4: 24-33 (2014)
  19. Anand R., Gill K., Mahdi A.: Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology 76: 27-50 (2014)
  20. Huang Y., Mucke L.: Alzheimer Mechanisms and Therapeutic Strategies. Cell 148(6): 1204-1222 (2012)
  21. Wixted J.: On common ground: Jost’s (1997) law of forgetting and Ribot’s (1881) law of retrograde amnesia. Psychol. Rev. 111(4): 864-879 (2004)
  22. Yaari R., Corey-Bloom J.: Alzheimer’s disease. Semin. Neurol. 27(1): 32-41 (2007).
  23. Yesavage J., Taylor J., Kraemer H., Noda A., Friedman L., Tinklenberg J.: Sleep-wake cycle disturbance in Alzheimer’s disease: How much is due to inherent tract? Int. Psychogeriatr. 14(1): 73-81 (2002)
  24. Bekris L., Yu C., Bird T., Tsuang D.: Genetics of Alzheimer Disease. J. Geriatr. Psychiatry Neurol. 23(4): 213-227 (2010)
  25. Chan T., Lam L., Prince M.: Validity and applicability of the Chinese version of Community Screening Instrument for Dementia. Dement. Geriatr. Cogn. Disord. 15(1): 10-18 (2003)
  26. Liu S., Prince M., Chiu M., Chen T., Sun Y., Yip P.: Validity and reliability of a Taiwan Chinese version of the Community Screening Instrument for Dementia. Am. J. Geriatr. Psychiatry 13(7): 581-588 (2005)
  27. DuBois B., Feldman H., Jacova C., Dekosky S., Bar-berger-Gateau P., Cumming J., Delacourte A.,Galasko D.,Gauthier S., Jicha G., Meguro K., O’brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P.: Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8): 734-746 (2007)
  28. Sweeney M., Sagare A., Zlokovic B.: Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer’s disease. J. Cereb. Blood Flow Metab. 35(7): 1055-1068 (2015)
  29. Duara R., Lowestein D., Potter E., Appel J., Greig M., Urs R., et al.: Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer’s disease. Neurology 71: 1986-1992 (2008)
  30. Desikan R., Cabral H., Fischl B., Guttmann C., Blacker D., Hyman B., Albert M.S., Killiany R.J.: Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. AJNR Am. J. Neuroradiol. 30(3): 532-538 (2009).
  31. Zhang L., Chang R., Chu L., Mak H.: Current neuro-imaging techniques in Alzheimer’s disease and applications in animal models. Am. J. Nucl. Med. Mol. Imaging 2(3): 386-404 (2012)
  32. Carter H., Jones M.: Positron emission tomography imaging in dementia. Br. J. Radiol. 80(2): 160-167 (2007)
  33. Ossenkoppele R., Jansen W., Rabinovici G., Knol D., Van der Flier W.: Prevalence of Amyloid PET Positivity in Dementia Syndromes. A Meta-analysis FREE. JAMA 313(19): 1939-1950 (2015)
  34. Roberson E., Mucke L.: 100 years and counting: Prospects for defeating Alzheimer’s disease. Science 314: 781-784 (2006)
  35. Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M.: Alzheimer’s disease: Clinical trials and drug development. Lancet Neurol. 9: 702-716 (2010).
  36. Koliopoulos T., Babatsikou F., Koutis C.: Evaluation Design of a Care Communal Building Facility for People with Alzheimer’s disease. Int. J. Caring Sci. 9(1): 348-357 (2016)
  37. Doody R., Stevens J., Beck C., Dubinsky R., Kaye J., Gwyther L., Mohs R.C.,Thal L.J.,Whitehouse P.J., DeKosky S.T., Cummings J.L..: Practice parameter: Mana-gement of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Aca-demy of Neurology. Neurology 56(9): 1154-1166 (2001)
  38. Geldmacher D.: Donepezil for treatment of Alzheimer’s disease and other dementing conditions. Expert. Rev. Neurother. 4: 5-16 (2004).
  39. Geldmacher D.: Cost-effectiveness of drug therapies for Alzheimer’s disease. A brief review. Neuropsychiatr. Dis. Treat. 4: 549-555 (2008)
  40. Witt A., Macdonald N., Kirkpatrick P.: Memantine hydrochloride. Nat. Rev. Drug Discov. 3: 109-110 (2004)
  41. Atri A., Shaughnessy L., Locascio J., Growdon J.: Long-term course and effectiveness of combination therapy in Alzheimer’ disease. Alzheimer Dis. Assoc. Disord. 22: 209-221 (2008)
  42. Yaari R., Corey-Bloom J.: Alzheimer’s disease. Semin. Neurol. 27: 32-41 (2007)
  43. Nicoll J., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat. Med. 9: 448-452 (2003)
Relative Papers

Online ISSN 1011-6575

 

 

 

Bookmark the permalink.

Comments are closed.